<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Access Maced J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Open Access Maced J Med Sci</journal-id><journal-title-group><journal-title>Open Access Macedonian Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="epub">1857-9655</issn><publisher><publisher-name>Institute of Immunobiology and Human Genetics</publisher-name><publisher-loc>Republic of Macedonia</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27275258</article-id><article-id pub-id-type="pmc">4877827</article-id><article-id pub-id-type="publisher-id">OAMJMS-3-403</article-id><article-id pub-id-type="doi">10.3889/oamjms.2015.088</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science</subject></subj-group></article-categories><title-group><article-title><italic>Bifidobacterium lactis</italic> in Treatment of Children with Acute Diarrhea. A Randomized Double Blind Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>El-Soud</surname><given-names>Neveen Helmy Abou</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Said</surname><given-names>Reem Nabil</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mosallam</surname><given-names>Dalia Sayed</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Barakat</surname><given-names>Nahla Abdel Moniem</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sabry</surname><given-names>Mohamed Ahmed</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Complementary Medicine Department, Medical Researches Division, National Research Center, El-Behouth Street, 12311 Cairo, Egypt</italic></aff><aff id="aff2"><label>2</label><italic>Pediatric Department, Faculty of Medicine, Cairo University, Cairo, Egypt</italic></aff><aff id="aff3"><label>3</label><italic>Pediatric Department, National Research Center, El-Behouth Street, 12311 Cairo, Egypt</italic></aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Prof. Dr. Neveen Helmy Abou El-Soud. Complementary Medicine Department, Medical Researches Division, National Research Center, El-Behouth Street, 12311 Cairo, Egypt. Tel: +02201224359509. E-mail: <email xlink:href="neveenster@gmail.com">neveenster@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>8</month><year>2015</year></pub-date><pub-date pub-type="ppub"><day>15</day><month>9</month><year>2015</year></pub-date><volume>3</volume><issue>3</issue><fpage>403</fpage><lpage>407</lpage><history><date date-type="received"><day>09</day><month>6</month><year>2015</year></date><date date-type="rev-recd"><day>10</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Neveen Helmy Abou El-Soud, Reem Nabil Said, Dalia Sayed Mosallam, Nahla Abdel Moniem Barakat, Mohamed Ahmed Sabry.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>BACKGROUND:</title><p>Probiotics are becoming increasingly popular treatment for children diarrhea. Although there are several probiotic strains potentially useful, researches were often limited to certain strains.</p></sec><sec id="st2"><title>AIM:</title><p>To test <italic>Bifidobacterium lactis</italic> on morbidity of acute diarrhea in children less than 2 years.</p></sec><sec id="st3"><title>SUBJECTS AND METHODS:</title><p>A randomized double-blind controlled clinical trial was conducted in 50 children (1 - 23 months) admitted with acute diarrhea to the Pediatric Hospital, Cairo University and were randomly assigned to receive in addition to usual treatment of diarrhea according to WHO guidelines; one of two treatments either milk formula non-supplemented (n = 25) or supplemented (n = 25) with <italic>Bifidobacterium lactis</italic> 14.5 &#x000d7; 10<sup>6</sup> CFU/100 ml daily for one week. Primary outcomes were frequency and duration of diarrhea and hospital stay. Secondary outcomes were duration of fever and vomiting episodes. Safety and tolerance were also recorded.</p></sec><sec id="st4"><title>RESULTS:</title><p>On admission, patients&#x02019; characteristics of both groups (50 cases) were similar. For children who received the probiotics for one week; mean duration of diarrhoea was shorter than in controls (3.12 &#x000b1; 0.92 vs. 4.10 &#x000b1; 0.94 days) (P = 0.02), number of motions per day was less than in controls (3.96 &#x000b1; 0.62 vs. 4.46 &#x000b1; 0.85) (P = 0.04) and discharge from hospital &#x0003c;2 days was more frequent than in controls (72% vs. 44%) (P = 0.048). There was no effect on fever (P = 0.63) or vomiting (P = 0.54).</p></sec><sec id="st5"><title>CONCLUSION:</title><p><italic>Bifidobacterium lactis</italic> probiotics in supplemented milk formula decreased significantly frequency, duration of diarrhea, and hospital stay than usual treatment alone in children with acute diarrhea. Additional researches on other uncommon local probiotic species should be encouraged.</p></sec></abstract><kwd-group><kwd>probiotics</kwd><kwd><italic>Bifidobacterium lactis</italic></kwd><kwd>acute diarrhea</kwd><kwd>children</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>The use of probiotics, discussed primarily in the context of alternative medicine and now entering mainstream medicine, only a few have been confirmed in well-designed controlled trials [<xref rid="ref1" ref-type="bibr">1</xref>].</p><p>Probiotics according to FAO/WHO [<xref rid="ref2" ref-type="bibr">2</xref>] are live microorganisms which when administered in adequate amounts confer a health benefit on the host. Research studies on probiotics vary according to type of genera, species and strain used beside additional intervention characteristics such as the dose, potency, treatment duration, viability of the organism, as well as the combination of strains [<xref rid="ref3" ref-type="bibr">3</xref>]. Of the probiotics derived from food sources (cultured milk products); lactic acid bacteria (e.g., <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic>), <italic>Saccharomyces boulardii</italic> (a non-pathogenic strain of yeast), <italic>Enterococcus</italic>
<italic>faecium</italic>, <italic>Streptococcus thermophiles, Pediococcus acidilactici, Bacillus coagulans</italic> and a non-pathogenic strain of <italic>Escherichia coli</italic> (e.g., <italic>E. coli</italic> Nissle, 1917). In children, probiotics were recommended to be used in allergies, inflammatory bowel disease, irritable bowel syndrome and necrotizing enterocolitis [<xref rid="ref4" ref-type="bibr">4</xref>]. They are commonly used in treatment and prevention of acute diarrhea [<xref rid="ref5" ref-type="bibr">5</xref>, <xref rid="ref6" ref-type="bibr">6</xref>]. Application of probiotics in treating acute children diarrhoea has increasingly become a subject of research interest. It has been reported that probiotics decrease the duration of diarrhoea and fever significantly in children [<xref rid="ref7" ref-type="bibr">7</xref>].</p><p>The strongest evidence of a beneficial effect of probiotics has been established with <italic>L. rhamnosus</italic>
<italic>GG</italic> [<xref rid="ref8" ref-type="bibr">8</xref>] and <italic>B. lactis</italic>
<italic>BB-12</italic> [<xref rid="ref9" ref-type="bibr">9</xref>] for prevention and <italic>Lactobacillus reuteri SD2222</italic> for treatment of acute rotavirus diarrhea in children [<xref rid="ref10" ref-type="bibr">10</xref>]. Common strains used to treat diarrhea include: <italic>L. rhamnosus</italic> [<xref rid="ref11" ref-type="bibr">11</xref>], <italic>L. acidophilus</italic> [<xref rid="ref12" ref-type="bibr">12</xref>], <italic>L. casei</italic> [<xref rid="ref13" ref-type="bibr">13</xref>], <italic>L. reuteri</italic> [<xref rid="ref14" ref-type="bibr">14</xref>], <italic>B. bifidum</italic> [<xref rid="ref15" ref-type="bibr">15</xref>], <italic>B. longum</italic> [<xref rid="ref16" ref-type="bibr">16</xref>], <italic>S. boulardi</italic> [<xref rid="ref17" ref-type="bibr">17</xref>], <italic>E. faecium</italic> [<xref rid="ref18" ref-type="bibr">18</xref>]. Probiotics for diarrhea exert their action possibly through direct or indirect mechanisms including immune modulation, inhibition of pathogenic bacteria, enhancing barrier function and production of antimicrobial agents [<xref rid="ref19" ref-type="bibr">19</xref>].</p><p><italic>Bifidobacteria</italic> are particularly attractive as probiotics agent because they constitute the predominant colonic flora of breastfed infants and are thought to play a role in the decreased incidence of diarrhea in breastfed infants [<xref rid="ref20" ref-type="bibr">20</xref>].</p><p>However, there are few studies investigating the role of this probiotics. In this study we investigated the effect of using 14.5 &#x000d7; 10<sup>6</sup> CFU/100 ml daily of <italic>Bifidobacterium lactis</italic> in supplemented milk formula for children acute diarrhea.</p></sec><sec sec-type="methods" id="sec1-2"><title>Subjects and Methods</title><p>The study protocol was approved by the ethical committee of the National Research Center and Pediatric Department of Cairo University. Informed written consent was obtained from parents of children enrolled in the study.</p><p>Fifty children 1 to 23 months of age with acute diarrhea due to gastroenteritis were enrolled in this prospective, double blind, randomized study conducted on admitted children with acute diarrhea to the Paediatric Hospital, Cairo University between July and September 2014. Diarrhoea was defined as passage of three or more loose stools in the last 24 hours [<xref rid="ref21" ref-type="bibr">21</xref>].</p><p>Children with severe malnutrition (weight for height &#x0003c; 3 SD of WHO charts), dysentery (presence of visible blood in stools), clinical evidence of co-existing acute systemic illnesses (e.g. meningitis, sepsis, pneumonia) and clinical evidence of chronic disease (e.g. chronic gastrointestinal disease, chronic liver disease, and chronic renal disease) were excluded from the study. Subjects in whom probiotics were used in the preceding four weeks or if antibiotics were used for current episode of diarrhoea, were also excluded from the study.</p><p>Each patient&#x02019;s demographic data, medical history, feeding pattern and stooling characteristics were recorded. Feeding parameters included number of meals per day, response to food (on a 1&#x02013;5 scale), daily formula volume, and daily number of regurgitation, degree of dehydration, and the symptoms associated with gastroenteritis (duration of diarrhea, number of motions, fever, vomiting), duration of hospital stay, growth parameters, safety and tolerance were also recorded. Clinical assessment of dehydration was done according to clinical dehydration scale [<xref rid="ref22" ref-type="bibr">22</xref>].</p><p>Patients with severe dehydration had been excluded from the study. The patients estimated as moderate dehydration with no oral tolerance had needed to be hospitalized. From each patient with diarrhea a stool sample was analyzed for routine bacterial cultures (including <italic>Salmonella</italic>, <italic>Shigella</italic>, <italic>Campylobacter</italic>, and <italic>Yersinia</italic> species, excluding toxigenic <italic>Escherichia coli</italic>), rotavirus, ova and parasites, including <italic>Cryptosporidium</italic>.</p><sec id="sec2-1"><title>Randomization</title><p>All included children were randomized to receive either milk formula with <italic>Bifidobacterium Lactis</italic> (<italic>B. lactis</italic> group) or no probiotics milk formula (control group) using serially numbered sealed opaque envelopes.</p></sec><sec id="sec2-2"><title>Intervention</title><p>All the studied patients with acute diarrhea received the usual treatment according to WHO guidelines [<xref rid="ref20" ref-type="bibr">20</xref>]; in addition the <italic>B. lactis</italic> group received formula with <italic>Bifidobacterium Lactis</italic> using 14.5 &#x000d7; 10<sup>6</sup> CFU (colony forming unit)/100 ml daily for 7 days and the control group received milk formula with no <italic>Bifidobacterium Lactis</italic> for 7 days. During the study period, patients were followed up in the hospital; to elicit frequency of diarrhea, episodes of vomiting or fever per day and the total duration of diarrhea.</p></sec><sec id="sec2-3"><title>Statistical analysis</title><p>Data was grouped as patients and control and analyzed using SPSS for windows version 16.0 (SPSS Chicago, IL.). Parametric (numeric) data were expressed as mean (SD) and compared using independent sample t-test. Non parametric data were expressed as frequency (number, percent) and compared using Mann- Whitney U test. Two tailed significant values were considered when p&#x0003c; 0.05.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>Results</title><p>A total of 50 children below 2 years of age fulfilled the protocol inclusion and exclusion criteria; were enrolled in this study. The initial demographic and clinical data of the two groups studied; 25 patients receiving milk formula with <italic>Bifidobacterium Lactis</italic> (<italic>B. lactis</italic> group) and 25 receiving milk formula with no <italic>Bifidobacterium Lactis</italic> (control group) were illustrated in <xref ref-type="table" rid="T1">Table 1</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Study population baseline characteristics</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>B. lactis</italic> group (n = 25)</th><th align="left" rowspan="1" colspan="1">Control group (n = 25)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, months<xref ref-type="table-fn" rid="t1f1">*</xref></td><td align="left" rowspan="1" colspan="1">12.36 (6.07)</td><td align="left" rowspan="1" colspan="1">11.84 (6.56)</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender<xref ref-type="table-fn" rid="t1f2">**</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" rowspan="1" colspan="1">15 (60)</td><td align="left" rowspan="1" colspan="1">16 (64)</td><td align="left" rowspan="1" colspan="1">0.77</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">10 (40)</td><td align="left" rowspan="1" colspan="1">9 (36)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Body weight, kg<xref ref-type="table-fn" rid="t1f1">*</xref></td><td align="left" rowspan="1" colspan="1">9.52 (2.67)</td><td align="left" rowspan="1" colspan="1">8.51 (2.10)</td><td align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of diarrhea before randomization, hours<xref ref-type="table-fn" rid="t1f1">*</xref></td><td align="left" rowspan="1" colspan="1">48.31 (9.44)</td><td align="left" rowspan="1" colspan="1">51.03 (8.16)</td><td align="left" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Children with fever<xref ref-type="table-fn" rid="t1f2">**</xref></td><td align="left" rowspan="1" colspan="1">7 (28)</td><td align="left" rowspan="1" colspan="1">6 (24)</td><td align="left" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Children with vomiting<xref ref-type="table-fn" rid="t1f2">**</xref></td><td align="left" rowspan="1" colspan="1">5 (20)</td><td align="left" rowspan="1" colspan="1">6 (24)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr></tbody></table><table-wrap-foot><fn id="t1f1"><label>*</label><p>mean(SD)</p></fn><fn id="t1f2"><label>**</label><p>number (%).</p></fn></table-wrap-foot></table-wrap><p>There were no significant differences (<italic>P</italic> &#x0003e; 0.05) between the two groups at randomization in terms of age at entry, birth weight, gender, breastfeeding before the study. The mean daily formula volume did not differ significantly between the control and <italic>B. lactis</italic> group (means [SD]: 589.4 [76.0] vs 578 [69.7] mL, respectively; <italic>P</italic> = 0.288). Furthermore, no significant differences were observed between groups in terms of other feeding characteristics (daily number of meals, regurgitation and vomiting episodes).</p><p>The mean duration (hours) of diarrhea before treatment was 48.31 &#x000b1; 9.44 in (<italic>B. lactis</italic> group) and 51.03 &#x000b1; 8.16 in (control group) (<italic>P</italic> = 0.76). Percentage of fever in <italic>B. lactis</italic> group was 28% and 24% in control group (<italic>P</italic> = 0.63). Percentage of vomiting in <italic>B. lactis</italic> group was 20% and 24% in control group (<italic>P</italic> = 0.64).</p><p>After 7 days of treatment the primary (frequency and duration of diarrhea, hospital stay) and secondary outcomes (frequency of vomiting and duration of fever) as illustrated in <xref ref-type="table" rid="T2">Table 2</xref>, indicated that the mean duration of diarrhea (days) after treatment was significantly shorter in children receiving <italic>B. lactis</italic> (<italic>P</italic> = 0.03).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Primary and secondary outcome measures</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>B. lactis</italic> group (n = 25)</th><th align="left" rowspan="1" colspan="1">Control group (n = 25)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Duration of diarrhea after randomization, (days)<xref ref-type="table-fn" rid="t2f1">*</xref></td><td align="left" rowspan="1" colspan="1">3.12 &#x000b1; 0.92</td><td align="left" rowspan="1" colspan="1">4.10 &#x000b1; 0.94</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Episodes of diarrhea /day<xref ref-type="table-fn" rid="t2f1">*</xref></td><td align="left" rowspan="1" colspan="1">3.96 (0.62)</td><td align="left" rowspan="1" colspan="1">4.46 (0.85)</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of hospital stay<xref ref-type="table-fn" rid="t2f2">**</xref></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c; 2 days</td><td align="left" rowspan="1" colspan="1">18 (32)</td><td align="left" rowspan="1" colspan="1">11 (44)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003e; 2 days</td><td align="left" rowspan="1" colspan="1">7 (28)</td><td align="left" rowspan="1" colspan="1">14 (56)</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Episodes of vomiting / day<xref ref-type="table-fn" rid="t2f1">*</xref></td><td align="left" rowspan="1" colspan="1">3.21 (0.33)</td><td align="left" rowspan="1" colspan="1">3.55(0.06)</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of fever, days<xref ref-type="table-fn" rid="t2f1">*</xref></td><td align="left" rowspan="1" colspan="1">2.27 (0.85)</td><td align="left" rowspan="1" colspan="1">2.79 (0.64)</td><td align="left" rowspan="1" colspan="1">0.56</td></tr></tbody></table><table-wrap-foot><fn id="t2f1"><label>*</label><p>mean (SD)</p></fn><fn id="t2f2"><label>**</label><p>number (%).</p></fn></table-wrap-foot></table-wrap><p>Frequency of diarrhea (number of motions per day) after treatment was significantly lower in children receiving <italic>B. lactis</italic> (<italic>P</italic> = 0.04). The duration of hospital stay was significantly less in children receiving <italic>B. lactis</italic>; 32% of children receiving <italic>B. lactis</italic> discharged form hospital before 2 days compared to 44% of control group (<italic>P</italic> = 0.04). There was no significant difference regarding reduction in episodes of fever and duration of vomiting in both groups. No adverse effects were noted in both groups.</p></sec><sec sec-type="discussion" id="sec1-4"><title>Discussion</title><p>This randomized double-blind controlled clinical trial demonstrated that for children under two years of age suffering from acute diarrhea, administration of 14.5 &#x000d7;10<sup>6</sup> CFU/100 ml daily of <italic>Bifidobacterium Lactis</italic> in a supplemented milk formula for 7 days results in less frequent episodes with shortening of the duration of diarrhea and less duration of hospital stay.</p><p>Probiotics have been most extensively studied in the treatment of diarrheal diseases, where their efficacy can be considered well established. Only a limited number of probiotic strains have been tested, and, as the effects of different probiotic microorganisms are not equivalent, results cannot be generalized [<xref rid="ref1" ref-type="bibr">1</xref>].</p><p>There are many microorganisms that could potentially function as probiotics, of which <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> species are the most commonly used. The genus <italic>Bifidobacterium</italic> includes various Gram positive non-motile anaerobic bacteria. They are endosymbiotic inhabitants of the gastrointestinal tract and vagina of mammals, including humans [<xref rid="ref23" ref-type="bibr">23</xref>].</p><p>Strains of the genus <italic>Bifidobacterium</italic> are also often used as probiotic bacteria as they are known for their variety of resistance mechanisms to bile salts, which is important since the beneficial effects of probiotic bacteria must be generated in the presence of this biological fluid. It has even been proven that although bile tolerance is strain dependent, wild type-bile sensitive bifidobacteria strains can progressively adapt to the presence of bile salts by subculturing and gradually increasing concentration of bile [<xref rid="ref24" ref-type="bibr">24</xref>].</p><p>In addition, non-pathogenic species belonging to the class of <italic>Saccharomyces</italic>, <italic>Streptococcus</italic> and <italic>Lactococcus</italic> are also used as probiotics [<xref rid="ref25" ref-type="bibr">25</xref>]. Pathogens are microorganisms that may cause disease in their host. The ability to inhibit pathogens is one of the three main mechanisms of probiotics, barrier function enhancement and immune interactions being the other two. It is proposed that pathogen inhibition is facilitated through multiple mechanisms including: production of inhibitory substances (organic acids, H<sub>2</sub>O<sub>2</sub>, bacteriocins); nutrient competition; toxin removal/degradation; competition for sites of adherence (mucus, cell receptors); co-aggregation and virulence modulation; and induction of host immune responses by inducing immune-modulatory activity, including recruitment of CD4 + T-helper cells [<xref rid="ref26" ref-type="bibr">26</xref>].</p><p>Of the studies on probiotics effect in children diarrhea; a Cochrane review [<xref rid="ref27" ref-type="bibr">27</xref>] found that the use of <italic>LGG</italic> reduced the duration of diarrhea and mean stool frequency on day 2, while in a more recent systematic review [<xref rid="ref28" ref-type="bibr">28</xref>] <italic>LGG</italic> had no effect on the total stool volume but significantly reduced the duration of diarrhea compared with placebo or no treatment. <italic>LGG</italic> was more effective when used at a daily dose of &#x0003e;10<sup>10</sup> colony-forming units (CFU). Another Cochrane review [<xref rid="ref29" ref-type="bibr">29</xref>] documented that the use of <italic>S boulardii</italic> reduced the risk of diarrhea lasting &#x0003e;4 days. The use of <italic>S boulardii</italic> significantly reduced both the duration of diarrhea and the risk of diarrhea on day 3. Similar results were found using <italic>L reuteri</italic> DSM 17938 [<xref rid="ref30" ref-type="bibr">30</xref>].</p><p>Studies on <italic>B lactis</italic> are not frequent, one RCT [<xref rid="ref31" ref-type="bibr">31</xref>] conducted on 224 Chinese children ages 6 to 36 months evaluated the effect of a lactose-free formula supplemented with 2 doses of a mixture of <italic>B lactis</italic> B12 and <italic>S thermophilus</italic> TH4 compared with unsupplemented formula. Regardless of the dose used, the duration of diarrhea was the same in both groups. In our study we used <italic>B lactis</italic> in a daily dose of 14.5 million CUF/100 ml and this dose was sufficient to induce reduction in frequency and duration of diarrhea.</p><p>In the present study, based on the average daily intake of formula, the mean daily ingested dose of <italic>Bifidobacterium Lactis</italic> was 14.6 &#x000d7;10<sup>8</sup> CFU/day, and according to a recent study, oral administration of lactobacilli at levels ranging from 10<sup>8</sup> to 10<sup>10</sup> CFU/day has led to transient colonization of the infant gastrointestinal tract [<xref rid="ref32" ref-type="bibr">32</xref>]. Most of the stool pathogens in our series were probably viral. Stool analysis for rotavirus was positive in 66%, none of stool samples were positive for routine bacterial cultures. This finding is in accordance with many previous studies demonstrating that probiotic agents are able to treat intestinal infections, mainly of viral etiology [<xref rid="ref33" ref-type="bibr">33</xref>, <xref rid="ref34" ref-type="bibr">34</xref>].</p><p>The mechanisms by which probiotic agents might exert their therapeutic effect against viral pathogens in particular are mostly unknown. An increased humoral response, including an increase in IgA-specific antibody-secreting cells against rotavirus, was described in children with acute rota viral diarrhea who received Lactobacillus GG [<xref rid="ref35" ref-type="bibr">35</xref>]. Another study [<xref rid="ref36" ref-type="bibr">36</xref>] showed that dietary treatment using <italic>B. lactis</italic> HN019 can reduce the severity of weanling diarrhea associated with rotavirus and <italic>E. coli</italic>, possibly via a mechanism of enhanced immune-mediated protection. That study suggested that probiotic treatment may be an effective dietary means of preventing or limiting diarrhea in human infants.</p><p><italic>Bifidobacterium lactis</italic> was tested for prevention of diarrhea in a randomized control trial [<xref rid="ref37" ref-type="bibr">37</xref>] of a commercial probiotic containing <italic>Bifidobacterium lactis</italic> and <italic>S. thermophilus</italic> involved 157 infants, 6 to 36 months of age. That study found a significant difference in the incidence of antibiotic-associated diarrhea in children receiving probiotic-supplemented formula (16%) compared with non-supplemented children. Our study was applied for children with acute viral diarrhea with exclusion of antibiotic associated causes.</p><p>As regarding safety, no adverse effects were noted in our study. Bifidobacteria are generally regarded as nonpathogenic, because they occur naturally in the intestine. In many clinical trials these agents seem to be safe for the general pediatric populations and in particular in infancy [<xref rid="ref38" ref-type="bibr">38</xref>].</p><p>Depending on the presence of great variety of species and strain characteristics of probiotics, there is always a need for more controlled clinical studies investigating new types of probiotics.</p><p>We concluded that <italic>Bifidobacterium lactis</italic> probiotics in supplemented milk formula decreased significantly frequency, duration of diarrhea, and hospital stay than usual treatment alone in children with acute diarrhea. Additional researches on other uncommon local probiotic species should be encouraged.</p></sec></body><back><fn-group><fn fn-type="other"><p><bold>Competing Interests:</bold> The authors have declared that no competing interests exist.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Setty</surname><given-names>M</given-names></name><name><surname>Mrukowicz</surname><given-names>J</given-names></name><name><surname>Guandalini</surname><given-names>S</given-names></name></person-group><article-title>Probiotics in Gastrointestinal Diseases in Children: Hard and Not-So-Hard Evidence of Efficacy</article-title><source>Journal of Pediatric Gastroenterology and Nutrition</source><year>2006</year><volume>42</volume><fpage>454</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">16707966</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><collab>Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada April 30 and May 1</collab><year>2002</year></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempel</surname><given-names>S</given-names></name></person-group><article-title>Probiotics for diarrhoea</article-title><source>Indian J Med Res</source><year>2014</year><volume>139</volume><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">24820827</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fijan</surname><given-names>S</given-names></name></person-group><article-title>Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature Microorganisms with Claimed Probiotic Properties: An Overview of Recent Literature</article-title><source>Int J Environ Res Public Health</source><year>2014</year><volume>11</volume><fpage>4745</fpage><lpage>4767</lpage><pub-id pub-id-type="pmid">24859749</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>Upadhyay</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name><name><surname>Teotia</surname><given-names>N</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Jaiswal</surname><given-names>V</given-names></name></person-group><article-title>Lactobacillus GG for treatment of acute childhood diarrhoea: An open labelled, randomized controlled trial</article-title><source>Indian J Med Res</source><year>2014</year><volume>139</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">24820831</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Applegate</surname><given-names>JA</given-names></name><name><surname>Walker</surname><given-names>CLF</given-names></name><name><surname>Ambikapathi</surname><given-names>R</given-names></name><name><surname>Black</surname><given-names>RE</given-names></name></person-group><article-title>Systematic review of probiotics for the treatment of community-acquired acute diarrhea in children</article-title><source>BMC Public Health</source><year>2013</year><volume>13</volume><issue>Suppl 3</issue><fpage>S16</fpage><pub-id pub-id-type="pmid">24564646</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>S</given-names></name><name><surname>Upadhyay</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name><name><surname>Teotia</surname><given-names>N</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Jaiswal</surname><given-names>V</given-names></name></person-group><article-title>
<italic>Lactobacillus</italic> GG for treatment of acute childhood diarrhoea: An open-labelled randomized controlled trial</article-title><source>Indian J Med Res</source><year>2014</year><volume>139</volume><fpage>379</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">24820831</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Wanke</surname><given-names>M</given-names></name><name><surname>Patro</surname><given-names>B</given-names></name></person-group><article-title>Meta-analysis: the effects of <italic>Lactobacillus rhamnosus GG</italic> supplementation for the prevention of healthcare-associated diarrhoea in children</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><volume>34</volume><issue>9</issue><fpage>1079</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">21899584</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Vrese</surname><given-names>M</given-names></name><name><surname>Kristen</surname><given-names>H</given-names></name><name><surname>Rautenberg</surname><given-names>P</given-names></name><name><surname>Laue</surname><given-names>C</given-names></name><name><surname>Schrezenmeir</surname><given-names>J</given-names></name></person-group><article-title>Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity</article-title><source>J Dairy Res</source><year>2011</year><volume>78</volume><issue>4</issue><fpage>396</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">21871144</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guandalini</surname><given-names>S</given-names></name></person-group><article-title>Probiotics for prevention and treatment of diarrhea</article-title><source>J Clin Gastroenterol</source><year>2011</year><volume>45</volume><issue>Suppl</issue><fpage>S149</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21992955</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciccarelli</surname><given-names>S</given-names></name><name><surname>Stolfi</surname><given-names>I</given-names></name><name><surname>Caramia</surname><given-names>G</given-names></name></person-group><article-title>Management strategies in the treatment of neonatal and pediatric gastroenteritis</article-title><source>Infect Drug Resist</source><year>2013</year><volume>6</volume><fpage>133</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">24194646</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phavichitr</surname><given-names>N</given-names></name><name><surname>Puwdee</surname><given-names>P</given-names></name><name><surname>Tantibhaedhyangkul</surname><given-names>R</given-names></name></person-group><article-title>Cost-benefit analysis of the probiotic treatment of children hospitalized for acute diarrhea in Bangkok, Thailand</article-title><source>Southeast Asian J Trop Med Public Health</source><year>2013</year><volume>44</volume><fpage>1065</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">24450244</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>ZJ</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name></person-group><article-title>Role of <italic>Lactobacillus</italic> in the prevention of <italic>Clostridium difficile</italic>-associated diarrhea: A meta-analysis of randomized controlled trials</article-title><source>Chin Med J (Engl)</source><year>2013</year><volume>126</volume><fpage>4154</fpage><lpage>4161</lpage><pub-id pub-id-type="pmid">24229690</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Urba&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Chmielewska</surname><given-names>A</given-names></name><name><surname>Weizman</surname><given-names>Z</given-names></name><name><surname>Shamir</surname><given-names>R</given-names></name></person-group><article-title>Meta-analysis <italic>Lactobacillus reuteri</italic> strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children</article-title><source>Benef Microbes</source><year>2014</year><volume>5</volume><issue>3</issue><fpage>285</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">24463209</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Mrukowicz</surname><given-names>JZ</given-names></name></person-group><article-title>Use of probiotics in children with acute diarrhea</article-title><source>Paediatr Drugs</source><year>2005</year><volume>7</volume><issue>2</issue><fpage>111</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15871631</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Wen</surname><given-names>B</given-names></name><name><surname>Yin</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Genome Sequence of the Bacterium Bifidobacterium longum Strain CMCC P0001, a Probiotic Strain Used for Treating Gastrointestinal Disease</article-title><source>Genome Announc</source><year>2013</year><volume>1</volume><issue>5</issue><fpage>pii: e00716-13</fpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>LS</given-names></name><name><surname>Hou</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>ZJ</given-names></name><name><surname>Liu</surname><given-names>FR</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Shu</surname><given-names>LH</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>XH</given-names></name><name><surname>Han</surname><given-names>XX</given-names></name><name><surname>Cai</surname><given-names>XX</given-names></name><etal/></person-group><article-title>Prevention and treatment of diarrhoea with <italic>Saccharomyces boulardii</italic> in children with acute lower respiratory tract infections</article-title><source>Benef Microbes</source><year>2013</year><volume>1</volume><fpage>329</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">24311316</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempel</surname><given-names>S</given-names></name><name><surname>Newberry</surname><given-names>SJ</given-names></name><name><surname>Maher</surname><given-names>AR</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Miles</surname><given-names>JN</given-names></name><name><surname>Shanman</surname><given-names>R</given-names></name><name><surname>Johnsen</surname><given-names>B</given-names></name><name><surname>Shekelle</surname><given-names>PG</given-names></name></person-group><article-title>Probiotics for the prevention and treatment of antibiotic- associated diarrhea: A systematic review and meta-analysis</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>1959</fpage><lpage>1969</lpage><pub-id pub-id-type="pmid">22570464</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corcionivoschi</surname><given-names>N</given-names></name><name><surname>Drinceanu d Stef</surname><given-names>L</given-names></name><name><surname>Luca</surname><given-names>I</given-names></name><name><surname>Julean</surname><given-names>C</given-names></name><name><surname>Mingyart</surname><given-names>O</given-names></name></person-group><article-title>Probiotics &#x02013; identification and ways of action</article-title><source>Innovative Romanian Food Biotechnology</source><year>2010</year><volume>6</volume><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chouraqui</surname><given-names>JP</given-names></name><name><surname>Van Egroo</surname><given-names>LD</given-names></name><name><surname>Fichot</surname><given-names>MC</given-names></name></person-group><article-title>Acidified milk formula supplemented with <italic>bifidobacterium lactis</italic>: impact on infant diarrhea in residential care settings</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2004</year><volume>38</volume><issue>3</issue><fpage>288</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15076628</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="book"><collab>World Health Organization (WHO)</collab><source>The treatment of diarrhoea: a manual for physicians and other senior health workers - 4th rev</source><year>2005</year><publisher-loc>Geneva</publisher-loc><publisher-name>WHO</publisher-name><comment>WHO/COD/SER/80.2.2005</comment></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JN</given-names></name><name><surname>Goldman</surname><given-names>RD</given-names></name><name><surname>Srivastava</surname><given-names>R</given-names></name><name><surname>Parkin</surname><given-names>PC</given-names></name></person-group><article-title>Development of a clinical dehydration scale for use in children between 1 and 36 months of age</article-title><source>J Pediatr</source><year>2004</year><volume>145</volume><issue>2</issue><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">15289767</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name></person-group><article-title>Development of intestinal bifidobacteria and <italic>Lactobacilli</italic> in breast-fed neonates</article-title><source>Clin Nutr</source><year>2007</year><volume>26</volume><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="pmid">17507117</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noriega</surname><given-names>L</given-names></name><name><surname>Cuevas</surname><given-names>I</given-names></name><name><surname>Margolles</surname><given-names>A</given-names></name><name><surname>de los Reyes-Gavil&#x000e1;n</surname><given-names>CG</given-names></name></person-group><article-title>Deconjugation and bile salts hydrolase activity by <italic>Bifidobacterium</italic> strains with acquired resistance to bile</article-title><source>Int Dairy J</source><year>2006</year><volume>16</volume><fpage>850</fpage><lpage>855</lpage></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemaiswarya</surname><given-names>S</given-names></name><name><surname>Raja</surname><given-names>R</given-names></name><name><surname>Ravikumar</surname><given-names>R</given-names></name><name><surname>Isabel</surname><given-names>SC</given-names></name></person-group><article-title>Mechanism of Action of Probiotics</article-title><source>Brazilian archives of Biology and technology</source><year>2013</year><volume>56</volume><issue>1</issue><fpage>113</fpage><lpage>119</lpage></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jungersen</surname><given-names>M</given-names></name><name><surname>Wind</surname><given-names>A</given-names></name><name><surname>Johansen</surname><given-names>E</given-names></name><name><surname>Christensen</surname><given-names>JE</given-names></name><name><surname>Stuer-Lauridsen</surname><given-names>B</given-names></name><name><surname>Eskesen</surname><given-names>D</given-names></name></person-group><article-title>The Science behind the Probiotic Strain <italic>Bifidobacterium animalis</italic> subsp. lactis BB-12</article-title><source>Microorganisms</source><year>2014</year><volume>2</volume><fpage>92</fpage><lpage>110</lpage></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>SJ</given-names></name><name><surname>Martinez</surname><given-names>EG</given-names></name><name><surname>Gregorio</surname><given-names>GV</given-names></name><etal/></person-group><article-title>Probiotics for treating acute infectious diarrhoea</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><fpage>CD003048</fpage><pub-id pub-id-type="pmid">21069673</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Sko&#x000b4;rka</surname><given-names>A</given-names></name><name><surname>Ruszczyn&#x000b4;ski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children&#x02014;updated analysis of randomised controlled trials</article-title><source>Aliment Pharmacol Ther</source><year>2013</year><volume>38</volume><fpage>467</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">23841880</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>SJ</given-names></name><name><surname>Martinez</surname><given-names>EG</given-names></name><name><surname>Gregorio</surname><given-names>GV</given-names></name><etal/></person-group><article-title>Probiotics for treating acute infectious diarrhoea</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><fpage>CD003048</fpage><pub-id pub-id-type="pmid">21069673</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Urba&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Chmielewska</surname><given-names>A</given-names></name><name><surname>Weizman</surname><given-names>Z</given-names></name><name><surname>Shamir</surname><given-names>R</given-names></name></person-group><article-title>Meta-analysis: Lactobacillus reuteri strain DSM 17938 (and the original strain ATCC 55730) for treating acute gastroenteritis in children</article-title><source>Benef Microbes</source><year>2014</year><volume>5</volume><issue>3</issue><fpage>285</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">24463209</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effect of a lactose-free milk formula supplemented with <italic>bifidobacteria</italic> and <italic>streptococci</italic> on the recovery from acute diarrhoea</article-title><source>Asia Pac J Clin Nutr</source><year>2008</year><volume>17</volume><fpage>30</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">18364323</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petschow</surname><given-names>B</given-names></name><name><surname>Figueroa</surname><given-names>R</given-names></name><name><surname>Harris</surname><given-names>C</given-names></name><etal/></person-group><article-title>Comparison of intestinal colonization and tolerance following oral administration of different levels of <italic>Lactobacillus rhamnosus</italic> strain GG (LGG) in healthy term infants [abstract]</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2003</year><volume>36</volume><fpage>566</fpage></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matarese</surname><given-names>LE</given-names></name><name><surname>Seidner</surname><given-names>DL</given-names></name><name><surname>Steiger</surname><given-names>E</given-names></name></person-group><article-title>The role of probiotics in gastrointestinal disease</article-title><source>Nutr Clin Pract</source><year>2003</year><volume>18</volume><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">16215086</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isolauri</surname><given-names>E</given-names></name><name><surname>Ribeiro</surname><given-names>HC</given-names></name><name><surname>Gibson</surname><given-names>G</given-names></name><etal/></person-group><article-title>Functional foods and probiotics: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2002</year><volume>35</volume><fpage>S106</fpage><lpage>S109</lpage><pub-id pub-id-type="pmid">12192178</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kailam</surname><given-names>M</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name><name><surname>Soppi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Enhancement of the circulating antibody secreting cell response in human diarrhea by a human <italic>lactobacillus</italic> strain</article-title><source>Pediatr Res</source><year>1992</year><volume>32</volume><fpage>141</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">1324462</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Q</given-names></name><name><surname>Qu</surname><given-names>F</given-names></name><name><surname>Gill</surname><given-names>H.S</given-names></name></person-group><article-title>Probiotic Treatment Using <italic>Bifidobacterium lactis</italic> HN019 Reduces Weanling Diarrhea Associated With Rotavirus and <italic>Escherichia coli</italic>. Infection in a Piglet Mode</article-title><source>Journal of Pediatric Gastroenterology and Nutrition</source><year>2001</year><volume>33</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">11568519</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>NB</given-names></name><name><surname>Peret Filho</surname><given-names>LA</given-names></name><name><surname>Penna</surname><given-names>FJ</given-names></name></person-group><article-title>A randomized formula controlled trial of <italic>Bifidobacterium lactis</italic> and <italic>Streptococcus thermophilus</italic> for prevention of antibiotic-associated diarrhea in infants</article-title><source>J Clin Gastroenterol</source><year>2005</year><volume>39</volume><fpage>385Y9</fpage><pub-id pub-id-type="pmid">15815206</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsheikh</surname><given-names>A</given-names></name><name><surname>Weizman</surname><given-names>Z</given-names></name></person-group><article-title>Safety of infant formula supplemented with two strains of probiotics in early infancy [abstract]</article-title><source>Pediatr Res</source><year>2003</year><volume>53</volume><fpage>174A</fpage></element-citation></ref></ref-list></back></article>